Get the Stockscreener App
86.33
3.79%
3.15
After Hours:
85.00
-1.33
-1.54%
Ionis Pharmaceuticals Inc stock is traded at $86.33, with a volume of 2.65M.
It is up +3.79% in the last 24 hours and up +15.91% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
See More
Previous Close:
$83.18
Open:
$84.42
24h Volume:
2.65M
Relative Volume:
1.45
Market Cap:
$14.27B
Revenue:
$1.06B
Net Income/Loss:
$-326.58M
P/E Ratio:
-41.07
EPS:
-2.1022
Net Cash Flow:
$-977.73M
1W Performance:
+8.88%
1M Performance:
+15.91%
6M Performance:
+3.80%
1Y Performance:
+106.63%
1-Day Range:
$82.95
$86.67
1-Week Range:
$77.95
$86.67
52-Week Range:
$40.03
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
86.33 | 13.75B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Apr-10-26 | Resumed | Raymond James | Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Oct-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-26-25 | Upgrade | Goldman | Sell → Neutral |
| Sep-03-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-31-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-01-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study - Yahoo Finance
Ionis Pharmaceuticals stock leans on pipeline and Nasdaq trading - AD HOC NEWS
Novartis’ Pipeline Building Continues, Pelacarsen Readout Coming Soon (NYSE:NVS) - Seeking Alpha
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
Ionis Pharmaceuticals concludes REVEAL study pivotal cohort enrolment - Clinical Trials Arena
Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart.com
Ionis Pharmaceuticals director Joseph Klein III sells $910k in stock - Investing.com Canada
Form 4 Ionis Pharmaceuticals Inc For: 6 July By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Advances Obudanersen for Angelman Syndrome - GuruFocus
Ionis finishes patient enrollment in Phase 3 rare disease trial - grafa.com
Ionis Pharmaceuticals, Inc. Completes Enrollment in Pivotal Cohort of Phase 3 REVEAL Study Evaluating Obudanersen in Angelman Syndrome - marketscreener.com
Ionis Pharmaceuticals (IONS) Advances Phase 3 REVEAL Study for A - GuruFocus
Ionis completes enrollment in Angelman syndrome drug trial By Investing.com - Investing.com Canada
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome - Business Wire
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring a 29.48% Potential Upside in the Biotech Sphere - DirectorsTalk Interviews
IONS out-licenses ex-US rights for rare neurology drug to Recordati - MSN
IONS News | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
TimesSquare Mid Cap Growth Strategy Picks Ionis Pharmaceuticals (IONS) on Clinical Momentum - Yahoo Finance
Form 144 IONIS PHARMACEUTICALS INC For: 1 July By Investing.com - Investing.com India
IONSIonis Pharmaceuticals Inc Latest SEC Filings - Finviz
Ionis Pharmaceuticals EVP Schneider sells $2.1m in stock - Investing.com UK
Ionis Pharmaceuticals EVP Joseph Baroldi’s spouse sells $451,698 stock - Investing.com UK
Ionis Pharmaceuticals EVP Joseph Baroldi’s spouse sells $451,698 stock By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals EVP Schneider sells $2.1m in stock By Investing.com - Investing.com Nigeria
Form 4 Ionis Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Trump's push for the world's lowest drug prices hits snag with mid-sized companies - marketscreener.com
Ionis Pharmaceuticals (IONS) Signs Recordati Deal For Zilganersen Outside The U.S. - Yahoo Finance
Why Ionis Pharmaceuticals (IONS) Is Up 9.5% After Dual TRYNGOLZA Approval and Zilganersen Out-Licensing Deal - Sahm
Ionis Pharmaceuticals (IONS) Is Up 9.5% After FDA Expands Tryngolza Label For Severe Hypertriglyceridemia - Yahoo Finance
Price to book forward of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS - TradingView
Enterprise value to EBITDA forward of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS - TradingView
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Insider Sell: Brett Monia Sells 85,637 Shares of Ionis Pharmaceu - GuruFocus
Form 144 IONIS PHARMACEUTICALS INC For: 26 June - Investing.com UK
Ionis (IONS) Wins Tryngolza Approval And Recordati Deal For Zilganersen - Sahm
Ionis CEO Brett Monia sells $6.8 million in company shares By Investing.com - Investing.com Nigeria
Price to earnings forward of Ionis Pharmaceuticals, Inc. – SWB:ISI - TradingView
Enterprise value to revenue forward of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS - TradingView
(IONS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Form 144 IONIS PHARMACEUTICALS INC For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of Ionis Pharmaceuticals, Inc. – SWB:ISI - TradingView
Ionis Pharmaceuticals EVP research Eric Swayze sells $839k in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP research Eric Swayze sells $839k in stock - Investing.com Australia
Form 4 Ionis Pharmaceuticals Inc For: 26 June By Investing.com - Investing.com Nigeria
Ionis CEO Brett Monia sells $6.8 million in company shares - Investing.com
Ionis Pharmaceuticals, Inc. Actuals & Estimates (HAM:ISI) - TradingView
Ionis Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:IONS) - TradingView
Form 144 | Ionis Pharmaceuticals(IONS.US) Officer Proposes to Sell 3.88 Million in Common Stocks - Moomoo
Ionis Pharmaceuticals, Inc. Actuals & Estimates (DUS:ISI) - TradingView
Ionis Pharmaceuticals(IONS.US) Officer Sells US$6.83 Million in Common Stock - Moomoo
Ionis Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ionis Pharmaceuticals Inc Stock (IONS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KLEIN JOSEPH III | Director |
Jul 01 '26 |
Sale |
79.04 |
11,518 |
910,416 |
11,014 |
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):